ClinicalTrials.gg
Active, not recruitingNCT06996912Updated Jan 2, 2026

A Study for HSK44459 in Participants With Atopic Dermatitis

A Phase 2 interventional study of HSK44459 and Placebo in Atopic Dermatitis (AD), sponsored by Xizang Haisco Pharmaceutical Co., Ltd. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-02.

Sponsored by Xizang Haisco Pharmaceutical Co., Ltd (part of Haisco Pharmaceutical Group Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Planned enrollment
106th of 190
150 · median 164
Started
2025
with 33 others
Phase 2
58 of 206
16 open now
Primary completion
2026-01
later than 18 of 81 live
Registered
147th of 206
by date

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 106th largest by planned enrollment of the 190 interventional ones that give a count, is one of 34 that started in 2025, is one of 58 in phase 2, reaches primary completion later than 18 of the 81 other live ones, and was the 147th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of HSK44459 in adults with Atopic Dermatitis

Read the detailed description

This is a multicenter, randomized, double-blind, parallel group, placebo controlled phase 2 study to assess the efficacy and safety of HSK44459 in adult participants with Atopic Dermatitis.

03

Conditions studied

  • Atopic Dermatitis (AD)

Browse trials for

Keywords

  • Atopic dermatitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained
  • Male or female, ≥18 years old and ≤75 years old
  • Willing and able to comply with study-specific procedures and the requirements of this study protocol.
  • Atopic dermatitis has been present for at least 1 year and subject meets Hanifin and Rajka criteria
  • EASI score≥16 at the screening and baseline visits
  • IGA score≥3 at the screening and baseline visits
  • ≥10% body surface area (BSA) of AD involvement at the screening and baseline visits
  • Baseline WI-NRS≥4
  • History of inadequate response to TCS of medium to higher potency (with or without topical calcineurin inhibitors [TCI]) or systemic treatment for AD within 6 months prior to screening
  • Have applied a stable dose of topical emollient (moisturizer) twice daily for at least 7 days before the baseline visit

Exclusion criteria

Exclusion Criteria:

  • Subjects have used AD treatments within the time frame specified in protocol prior to the baseline visit
  • Prior exposure to any PDE4 inhibitor systemic treatment
  • Systemic use of known strong inhibitors or strong CYP3A inducers within 4 weeks or 5 half-lives prior to randomization or during the course of the study
  • Participation in other clinical studies within 4 weeks or 5 half-lives prior to randomization
  • Subjects have laboratory values meeting the criteria in protocol
  • Presence of skin comorbidities that may interfere with study assessments
  • Concurrent conditions and history of other diseases as described in protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    HSK44459-Dose level 1

    Participants will receive HSK44459 for 12 weeks

    Drug: HSK44459

  • Experimental
    HSK44459-Dose level 2

    Participants will receive HSK44459 for 12 weeks

    Drug: HSK44459

  • Placebo comparator
    Placebo

    Participants will receive Placebo for 12 weeks

    Drug: Placebo

Interventions

  • HSK44459 will be administered orally twice daily

  • DrugPlacebo

    Placebo will be administered orally twice daily

06

What researchers measure

Primary outcomes

  1. Percent change from baseline to week 12 in EASI

    Evaluate the clinical efficacy of 2 dose levels of HSK44459, compared to placebo, in adult participants with atopic dermatitis (AD) using EASI. A total EASI score range from 0 to 72 points will be recorded for each assessment, with higher scores reflecting worse severity of AD

    Time frame: From Day 1 (first dose) to Day 85 (week 12)

Secondary outcomes

  1. Proportion of patients with EASI-75 at week 12

    Proportion of patients with EASI-75 (≥75% improvement from baseline) at week 12

    Time frame: From Day 1 (first dose) to Day 85 (week 12)

  2. Proportion of patients with both IGA 0 to 1and a reduction from baseline of ≥2 points at week 12

    The IGA determines severity of AD and clinical response to treatment on a 5-point scale 0 = Clear 1. = Almost clear 2. = Mild 3. = Moderate 4. = Severe

    Time frame: From Day 1 (first dose) to Day 85 (week 12)

  3. Proportion of patients with reduction of pruritus WI-NRS ≥3 or WI-NRS ≥4 from baseline to week 12

    The WI-NRS ranges from 0 = "no itch" to 10 ="worst imaginable itch" for the worst intensity itch in the preceding 24-hour period.

    Time frame: From Day 1 (first dose) to Day 85 (week 12)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jan 2026, 7 months after the start.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 7 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2025
First posted
May 30, 2025
StartActual
May 22, 2025
Primary completionEst.
Jan 20, 2026
CompletionEst.
Mar 23, 2026
Last update
Jan 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06996912
Responsible party
Sponsor
First posted
May 30, 2025
Start date
May 22, 2025
Primary completion
Jan 20, 2026 (estimated)
Completion
Mar 23, 2026 (estimated)
Last update
Jan 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK44459

Start the discussion